Highlights

• Founded in 2005 to pursue disruptive and proprietary technology Greffex’s founders first explored in 1998
• Awarded patents in 2014 for the creation of a fully-deleted, helper-independent adenoviral vector platform
• Greffex vectors are clean, safe, stable, versatile, and manufactured in a standardized, cost efficient process
• When applied to vaccines, the universally applicable platform eliminates the need for refrigeration and it can produce doses more quickly, with less lead time, and more cheaply than traditional vaccines
• NIH-sponsored third-party animal trials demonstrated an impressive 100% protection against a deadly pandemic influenza strain (versus FDA standard of 70% in animals and 40% in humans)
• Using the target disease’s genetic sequence, Greffex can create any vaccine in 3-4 weeks and produce 100 million doses in 90 days at a fraction of the cost of traditional vaccine production
• Greffex presently holds 12 patents with 9 additional filings